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Abstract 
The androgen and androgen receptor (AR)-regulated gene expression plays important roles 
in normal prostate and prostate cancer development, and AR transcriptional control of 
genes is mediated by transcriptional coactivators, including the three members of the steroid 
receptor coactivator (SRC) family, SRC-1 (NCOA1), SRC-2 (TIF2/GRIP1/NCOA2) and 
SRC-3 (AIB1, ACTR/RAC3/NCOA3). SRC-1 and SRC-3 are overexpressed in multiple human 
endocrine cancers and knockdown of either one of them in prostate cancer cell lines im-
pedes cellular proliferation. Knockout of SRC-3 in mice suppresses the progression of 
spontaneous prostate carcinogenesis. In this study, we investigated SRC-1 contribution to 
prostate cancer in vivo by deleting the SRC-1 gene in TRAMP mice, which contain the pro-
basin promoter-driven SV40 T/t antigen transgene. In assessing tumor mass of mice at vari-
ous ages, we found that initiation and progression of prostate cancer induced by SV40 T/t 
antigens were unaltered in SRC-1
-/- mice versus WT mice. Primary tumor histology and me-
tastasis to distant lymph nodes were also similar in these mice at all time points assessed. 
These results demonstrate that the role of SRC-1 in mouse prostate carcinogenesis is non-
essential and different from the essential contribution of SRC-3 that is required for prostate 
cancer progression and metastasis in mice. Interestingly, we observed that during prostate 
tumorigenesis SRC-1 expression was relatively constant, while SRC-3 expression was signifi-
cantly elevated. Therefore, the loss of SRC-1 function may be compensated by SRC-3 over-
expression during prostate tumorigenesis in SRC-1
-/- mice. 
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INTRODUCTION 
Prostate cancer is the most common malignancy 
among American men and second leading cause of 
cancer death (1). Early in their development, prostate 
tumors require androgen stimulation for growth and 
survival. Therein they respond to androgen depriva-
tion therapy. Following remission, however, tumors 
frequently recur in an androgen-independent form 
refractory to current treatment modalities (2). Under-
standing the development and progression of pros-
tate cancer through androgen-dependent and inde-
pendent stages is essential for devising novel targeted 
therapeutic strategies.   
The androgen receptor (AR) signaling pathway 
is involved in development and progression of pros-
tate cancer (3). Androgen receptor is a member of the 
nuclear receptor superfamily, a collection of proteins Int. J. Biol. Sci. 2009, 5 
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with hormone-activated transcriptional activities. 
Transcriptional control by nuclear receptors depends 
not only on the presence and concentration of appro-
priate hormone but also on regulation by coactivator 
molecules. Coactivators associate with hor-
mone-bound receptors at the gene site and recruit 
general transcription machinery. Therefore, coactiva-
tor expression level and activity may profoundly alter 
the transcriptional activities of nuclear receptors (4, 
5). The best-characterized coactivators comprise the 
steroid receptor coactivator (SRC) family. Its three 
members are 160-kDa proteins termed SRC-1 
(NCOA1), SRC-2 (TIF2/GRIP1/NCOA2) and SRC-3 
(AIB1/p/CIP/RAC3/ACTR/TRAM-1/NCOA3). 
Extensive studies in knockout mice demonstrate in-
volvement of the SRC family in regulating normal 
development and physiology. Genetic disruption of 
SRC-1 in mice results in partial steroid hormone re-
sistance in reproductive organs such as uterus, pros-
tate, testis, and mammary gland (5). Deletion of 
SRC-2 causes reproductive impairment and hypofer-
tility in both male and female mice (6, 7). SRC-3 null 
(SRC-3-/-) mice exhibit somatic growth retardation, 
female reproductive dysfunction and mammary 
gland growth reduction (8, 9). Therein, SRC family 
members have critical roles in development and 
maintenance of normal tissues.   
Several groups, including our own, have dem-
onstrated important roles for SRC proteins in multi-
ple cancers (10-15). We exploited SRC-3 -/- mice to de-
termine that SRC-3 deficiency suppresses mammary 
gland tumor development induced either by onco-
genes or chemical carcinogens (11, 12, 16). We identi-
fied an association between SRC-3 and prostate can-
cer in the SV40-induced transgenic adenocarcinoma 
of the mouse prostate (TRAMP) model, noting in-
crease in SRC-3 expression in prostatic luminal 
epithelial cells during tumorigenesis. To further in-
vestigate the relationship, we crossed TRAMP and 
SRC-3-/- mice. Remarkably, prostate cancer progres-
sion observed in these bigenic animals was markedly 
delayed and much more differentiated than those 
observed in WT/TRAMP mice. In vitro studies dem-
onstrating the requirement of SRC-3 for prostate can-
cer cell proliferation and survival confers our find-
ings (10, 14). In addition, SRC-3 directly regulates 
transcription of matrix metalloproteinases, MMP-2, 
MMP-9 and MMP-13, to potentiate cancer cell inva-
sion and metastasis (15, 16). 
SRC-1 has also been linked to prostate cancer. A 
clinical study showed increased SRC-1 protein in 
hormone-refractory prostate tumors compared with 
benign prostatic hyperplasia or androgen-dependent 
tumors (17). A second study showed increased SRC-1 
expression in localized androgen dependent prostate 
tumors correlates with increased metastases to dis-
tant lymph nodes (18). Moreover, in vitro analyses 
demonstrate that SRC-1 knockdown represses the 
activation of AR target genes and reduces 
AR-dependent cellular proliferation (18).   
In the current study, we investigate the role of 
SRC-1 in an in vivo model of prostate cancer. We cre-
ated a bigenic mouse model in which SRC-1-/- mice 
were crossed with TRAMP mice. Surprisingly, inac-
tivation of SRC-1 did not inhibit prostate cancer ini-
tiation and progression, as tumors in bigenic mice 
were morphologically similar to those of 
WT/TRAMP mice. These results are at odds with our 
findings in the SRC-3-/- TRAMP bigenic and also con-
tradict published in vitro and clinical findings. Inter-
estingly, we observed an increase in SRC-3 expression 
in the prostate tumors of both WT/TRAMP and 
SRC-1-/-/TRAMP mice. Therefore, SRC-3 may com-
pensate for the absent SRC-1 in promoting prostate 
tumorigenesis in this model. In conclusion, our 
analysis of prostate carcinogenesis in TRAMP model 
with a SRC-1 null background demonstrates that 
SRC-1 is not an essential coactivator to drive prostate 
cancer initiation and progression. 
 
MATERIALS AND METHODS 
Mice. SRC-1-/- mice were initially generated as 
described (5), and subsequently backcrossed into a 
C57BL/6J strain background. TRAMP mice with 50% 
C57BL/6J and 50% 129SvEV genetic contribution and 
harboring the Probasin-SV40 T/t transgene were 
produced as previously reported (19). To generate 
SRC-1-/-/TRAMP mice, SRC-1-/- m i c e  i n  C 5 7 B L / 6 J  
genetic background were crossed with 50% 
C57BL/6J-50% 129SvEV TRAMP mice. The offspring 
were backcrossed with C57BL/6J SRC-1-/- mice three 
times to generate 93.75% C57BL/6J-6.25% 129SvEV 
(experimental)  SRC-1-/-/TRAMP and (control) 
SRC-1+/+ (WT)/TRAMP mice. This breeding strategy 
ensured all experimental mice were hemizygous for 
the TRAMP transgene. Genotyping was performed 
via PCR-based screening assay on DNA extracted 
from ear tip biopsy by proteinase K digestion. For 
TRAMP mice, primer sequences were 
5’-CCGGTCGACCGGAAGCTTCCACAAGTGCATT
TA (forward) and 5’-CTCCTTTCAAGACCTAGAAG 
GTCCA (reverse). SRC-1 knockout mice were geno-
typed as described previously (5). 
Tissue examination and Histology. TRAMP and 
bigenic mice were weighed, anesthetized and sacri-
ficed at 8, 12, 18, 24 and 30 weeks of age. All major 
organs were inspected for evidence of tumors, while Int. J. Biol. Sci. 2009, 5 
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lymph nodes were assessed for metastases. The entire 
genitourinary (GU) tract, consisting of the bladder, 
urethra, seminal vesicles, ampullary gland, and pros-
tate, was excised and dissected under low power mi-
croscope. The wet weights of the GU tract, seminal 
vesicles, and prostate were recorded. Tissues were 
fixed in 10% buffered formalin for 12 hr at 4oC, dehy-
drated in sequentially increasing ethanol concentra-
tions, processed and embedded in paraffin blocks. 
Sections of 5 μm thickness were stained with hema-
toxylin and eosin (H&E), and examined under a light 
microscope. Histopathology was determined accord-
ing to the GEM grading classification scheme in 
which prostatic intraepithelial neoplasia (PIN), 
well-differentiated adenocarcinoma (WDA), moder-
ately-differentiated adenocarcinoma (MDA) and 
poorly-differentiated adenoarcinoma (PDA) are 
qualitatively and quantitatively scored (20). 
Immnuohistochemistry.  All immunohisto-
chemical staining was performed on 5 μm 
de-parafinized sections. Antigen retrieval was carried 
out by incubating the slides in 0.01 M citric acid 
buffer (pH 6.0) using microwave method. Slides were 
then cooled and washed successively with PBS and 
deionized water. Next, endogenous peroxidase activ-
ity was inactivated by incubation in methanol con-
taining 3% hydrogen peroxide. Sections were subse-
quently incubated overnight at 4oC with following 
primary antibodies: Mouse monoclonal anti-T anti-
gen (BD Transduction Laboratory) (for detection of 
SV40 large T-antigen), goat polyclonal anti-SRC-1 
(Santa Cruz) and rabbit polyclonal anti-SRC-3 (Cell 
Signaling) antibodies. Biotinylated secondary anti-
bodies, rabbit anti-mouse for TRAMP, horse anti-goat 
for SRC-1 and goat anti-rabbit for SRC-3 were used, 
and were each diluted 1:600. The Avidin Biotin Com-
plex kit (Vector Laboratories) was used for chromo-
phore-mediated detection. 
Immunoblotting analysis. Prostate samples 
designated for Western blot analysis were lysed in 
RIPA buffer and prepared as described (13). The fol-
lowing primary antibodies were used for detection: 
rabbit polyclonal anti-SRC-1 (Santa Cruz) and rabbit 
polyclonal anti-AIB1 (SRC-3) (gift from Dr. R. Wu, 
Baylor College of Medicine, Houston, TX). Horse 
radish peroxydase (HRP)-conjugated (goat) 
anti-rabbit secondary antibodies were used.   
RESULTS 
Loss of SRC-1 does not suppress prostate cancer 
tumorigenesis 
To study the contribution of SRC-1 to prostate 
cancer, we generated SRC-1-/-/TRAMP mice and 
compared formation and progression of genitouri-
nary tumors versus WT/TRAMP mice. We monitored 
tumor growth in each genotype, collecting tissue 
samples at 8, 12, 18, 24, and 30 weeks of age. At each 
time point, we assessed total body weight and indi-
vidual weights of GU tract, prostate and seminal 
vesicles. At all time points, SRC-1-/-/TRAMP mice 
had slightly lower body weight than WT/TRAMP 
mice (Fig. 1A). Relative GU tract weight (normalized 
to body weight) increased progressively with age in 
both  WT/TRAMP and SRC-1-/-/TRAMP mice. No 
statistically significant difference was observed be-
tween the two genotypes (Fig. 1B). Similarly, relative 
weights of prostate and seminal vesicle (each nor-
malized to body weight) were also unchanged be-
tween  WT/TRAMP and SRC-1-/-/TRAMP mice at 
each time point assessed (Fig. 1, C and D). Upon sac-
rifice, we inspected the GU tract under low power 
dissecting microscope and collected all identifiable 
tumors. No tumors were grossly visible in either 
genotype at the 8, 12 and 18-week time points. At the 
24-week time point, 6/8 SRC-1-/-/TRAMP and 7/9 
WT/TRAMP mice developed tumors. At 30 weeks, 
9/9 SRC-1-/-/TRAMP and 7/7 WT/TRAMP mice had 
large GU tract tumors. Tumors collected at both the 
24 and 30-week time points had similar gross mor-
phology between the WT/TRAMP and 
SRC-1-/-/TRAMP mice. Therefore, gross anatomical 
assessment suggests prostate tumorigenesis and local 
cancer progression are similar in SRC-1-/-/TRAMP 
and WT/TRAMP mice.   
In order to ascertain the impact of SRC-1 dele-
tion on tumor morphology, we performed histopa-
thological assessment of prostates from 
SRC-1-/-/TRAMP and WT/TRAMP mice at 8, 12, 18, 
24, and 30-week time points. 5 μm H&E-stained sec-
tions from mice of each genotype were subjected to 
morphological (GEM) analysis for cancer progression, 
taking into account relative abundance of PIN, WDA, 
MDA, and PDA tissues. While WT/TRAMP ap-
peared at 12 weeks to show a subtly advanced cancer 
versus SRC-1-/-/TRAMP, both genotypes had similar 
morphology at all subsequent time points (Fig. 2). 
Therefore, the histological analysis further indicates 
similar prostate tumor progression between 
SRC-1-/-/TRAMP and WT/TRAMP mice.   Int. J. Biol. Sci. 2009, 5 
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Fig. 1. Prostate tumor growth in SRC-1
-/-/TRAMP and WT/TRAMP mice. Body weight (panel A), genitourinary weight 
(panel B), seminal vesicle weight (panel C) and prostate weight (panel D) were recorded at sacrifice and the mean (± s.e.m.) 
relative organ weights are represented as a function of age and genotype. Relative weights are calculated by normalizing the 
organ weight to body weight. WT/TRAMP mice: 8 weeks, n=6; 12 weeks, n=10; 18 weeks, n=10; 24 weeks, n=9; 30weeks, 
n=7; SRC-1
-/-/TRAMP mice: 8 weeks, n=3; 12 weeks, n=8; 18 weeks, n=10; 24 weeks, n=8; 30weeks, n=11.  
 
 
Fig. 2. A) H&E stained histologic sections of the WT/TRAMP and SRC-1
-/-/TRAMP prostate tissues at different tumorigenic 
stages (Pathologic grades: PIN, prostatic intraepithelial neoplasia; WD, well-differentiated adenocarcinoma; MD, moderately 
differentiated adenocarcinoma; PD, poorly differentiated adenocarcinoma; PHY, phylloides-like cancer). Images were taken 
at x200 magnification and the scale bars represent 50 μm in length. B) Immunohistochemical analysis of SV40 T antigen 
expression in WT/TRAMP and SRC-1
-/-/TRAMP prostate tissues. Only dorsal lobes are shown here. The slides were 
counterstained with hematoxylin. Images were taken at x200 magnification and the scale bars represent 50 μm in length. 
Brown color, T antigen immunoreactivity. Note that T antigen expression levels are similar between SRC-1
-/-/TRAMP and 
WT/TRAMP prostates. Int. J. Biol. Sci. 2009, 5 
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Ablation of SRC-1 does not inhibit prostate 
cancer metastasis 
Clinical studies demonstrated that enhanced 
SRC-1 expression is associated with increased local 
invasiveness, metastatsis, and fatal disease progres-
sion (18). Therefore, we evaluated metastatic capacity 
of prostate tumors in SRC-1-/-/TRAMP versus 
WT/TRAMP mice. Specifically, we assessed periaor-
tic lymph nodes, lungs, and liver since these organs 
are common sites of metastasis in the TRAMP model 
(19). Following sacrifice, periaortic lymph nodes were 
weighed and observed under the dissecting micro-
scope. The relative (normalized to body weight) 
weight of the periaortic lymph nodes increased as a 
function of age in both SRC-1-/-/TRAMP and 
WT/TRAMP mice. Neither the overall rate of weight 
increase nor weights at individual time points were 
significantly different between the two genotypes 
(Fig. 3A). Moreover, we detected metastatic lesions in 
periaortic lymph nodes of both SRC-1-/-/TRAMP and 
WT/TRAMP mice. H&E staining of lymph node tis-
sue confirmed presence of tumors while SV40 im-
munohistochmistry demonstrated tumors were 
prostate-originated metastases (Fig. 3B). Metastases 
were evident at weeks of age in both genotypes and 
we observed no significant difference in the number 
or morphology of these lesions at any subsequent 
time point. In sum, no significant difference was 
observed in lymph node size or metastatic tumor 
morphology between the two genotypes at any time 
between 8 and 36 weeks of age.   
SRC-1 expression is relatively consistent 
throughout the stages of prostate cancer pro-
gression 
To check the SRC-1 expression patterns in 
TRAMP mouse prostate tissues, SRC-1 immunohis-
tochemistry was performed. SRC-1 was found to be 
expressed in luminal epithelial cells and tumor cells 
of the prostate tissue and the expression was consis-
tent with moderate level throughout the different 
stages of tumor progression (Fig. 4A). SRC-1 null 
prostate tissues were used as negative control (Fig. 
4A). We also carried out immunoblotting analysis to 
obtain semi-quantitative SRC-1 level in TRAMP mice. 
SRC-1 level did not increase progressively as a func-
tion of age and prostate cancer progression. In fact, 
SRC-1 protein level decreased between 18 and 24 
weeks of age (Fig. 4C). Protein lysates from 
SRC-1-null TRAMP prostates were used as negative 
controls (Fig. 4C). These results suggest that SRC-1 is 
not overexpressed during prostate carcinogenesis in 
mice.  
 
Fig. 3. A) The comparable weights of periaortic lymph 
nodes in WT/TRAMP and SRC-1
-/-/TRAMP mice. The 
weights of periaortic lymph nodes were recorded and the 
relative periaortic lymph node weight was calculated. The 
box-and-whisker plot presents the distribution of relative 
lymph node weights. Whiskers represent all data analyzed, 
excluding outliers (represented by black dots), black line 
indicates median, and box represents 25% of data greater 
than and less than median. WT/TRAMP mice: 8 weeks, 
n=6; 12 weeks, n=10; 18 weeks, n=10; 24 weeks, n=9; 30 
weeks, n=7; SRC-1
-/-/TRAMP mice: 8 weeks, n=3; 12 
weeks, n=8; 18 weeks, n=10; 24 weeks, n=8; 30 weeks, 
n=11.  B) Histological analysis of the periaortic lymph 
nodes from 24-week-old mice. Upper panel was H&E 
stained sections while the lower panel was immunostained 
with SV40 T antigen antibody to identify the cancer cells 
with a prostatic origin (brown color). LNC, lymph node 
cells; MTC, metastatic tumor cells. Images were taken at 
x200 magnification and the scale bars represent 50 μm in 
length. Int. J. Biol. Sci. 2009, 5 
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Fig. 4. Immunochemical analyses of SRC-1 and SRC-3 expression during prostate tumor initiation and progression. A) 
Immunohistochemistry for SRC-1 ,brown color, in the prostates of WT/TRAMP and SRC-1
-/-/TRAMP (negative control) mice 
with indicated ages. B) Immunohistochemistry for SRC-3, brown color, in the prostates of WT/TRAMP and SRC-1
-/-/TRAMP 
mice with indicated ages. A prostate sample of 24-week-old SRC-3
-/-/TRAMP mouse was used as negative control. Images 
were taken at x200 magnification and the scale bars represent 50 μm in length. C) Western blot analyses of SRC-1 and 
SRC-3 in the prostates and tumors of WT/TRAMP and SRC-1
-/-/TRAMP mice ages as indicated. Tubulin was used as a loading 
control. D) Western blot analyses of SRC-1 and SRC-3 in the prostates of WT (SRC-1
+/+, non-TRAMP) and SRC-1
-/- mice. 
β-actin was used as a loading control. The stronger bands in panel D compared with those in panel C were because of a 
longer exposure time to the X-ray films in an independent experiment.  
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Evaluation of SV40 T antigen and SRC-3 expres-
sion in the prostate tissue of SRC-1
-/-/TRAMP and 
WT/TRAMP mice. 
Immunohistochemistry demonstrates the pres-
ence of SV40 T antigen in SRC-1-/-/TRAMP and 
WT/TRAMP mouse prostate. SV40 T antigen immu-
nostaining was uniform throughout the luminal epi-
thelium of the prostate tissue. Prostate stromal cells, 
on the contrary, exhibited only scattered SV40 T an-
tigen expression (Fig. 2B). Therefore, SRC-1 defi-
ciency did not alter SV40 transgene expression.   
Protein levels of SRC-3 in SRC-1-/-/TRAMP and 
WT/TRAMP mouse prostates were examined by both 
immunohistochemistry and immunoblotting. In both 
WT/TRAMP and SRC-1-/-/TRAMP mice, SRC-3 im-
munoactivity was relatively low at 18 weeks of age in 
both normal and hyperplastic luminal epithelial cells, 
while at 24 weeks, SRC-3 immunoactivity was sig-
nificantly increased in the prostate tumor cells (Fig. 
4B). SRC-3 immunostaining specificity was validated 
by using SRC-3-null prostate as a negative control 
(Fig. 4B). 
Unlike SRC-1, SRC-3 protein level increased 
progressively during prostate carcinogenesis in 
WT/TRAMP mice as assayed by immunoblotting 
(Fig. 4C). Interestingly, at 12 weeks of age SRC-3 in 
the prostates of SRC-1-/-/TRAMP mice was signifi-
cantly higher than that in the prostates of 
WT/TRAMP mice, and this high level was main-
tained throughout the older age time points (Fig. 4C). 
These results demonstrate that SRC-3 is overex-
pressed during prostate carcinogenesis in the pros-
tates of both WT/TRAMP and SRC-1-/-/TRAMP mice 
and SRC-3 overexpression in SRC-1-/-/TRAMP mice 
comes earlier compared with WT/TRAMP mice.   
We also performed immunoblotting analysis to 
examine SRC-3 protein levels in the prostates of WT 
and SRC-1-/- mice. We found no difference in SRC-3 
levels between WT and SRC-1-/- prostates (Fig. 4D). 
These results suggest that SRC-1 ablation does not 
alter SRC-3 protein level in normal prostate and thus, 
SRC-3 overexpression is an event linked with prostate 
tumorigenesis. 
 
DISCUSSION 
Certain steroid receptor coactivators such as 
SRC-3 are putative oncogenes in multiple cancers. 
Our laboratory demonstrated inactivation of SRC-3 
could arrest prostate cancer at well-differentiated 
stages in TRAMP mice. Tumors in these mice neither 
progressed to poorly-differentiated stages nor metas-
tasized. In the current study, we show that SRC-1 
knockout does not arrest prostate cancer progression 
in TRAMP mice. Contrary to SRC-3-/-/TRAMP mice, 
SRC-1-/-/TRAMP mice develop prostate cancer at a 
similar rate and extent to WT/TRAMP mice. Both 
groups have similar tumor morphology and pattern 
of metastases.   
The failure of SRC-1 deletion to alter prostate 
cancer progression in the TRAMP model is at odds 
with clinical data correlating SRC-1 expression level 
and increased metastatic potential (18). One potential 
explanation for the contradiction is a requirement of 
SRC-1 overexpression for induction of more severe 
tumor phenotypes. Recently, we demonstrated that 
SRC-1 was upregulated in mammary tumors in 
MMTV-polyoma middle T transgenic mice, and that 
the overexpressed SRC-1 promoted tumor cell me-
tastasis through increasing HER2 and col-
ony-stimulating factor 1 (CSF-1) protein levels (21). In 
the present study, SRC-1 was not overexpressed and 
accordingly, its loss-of-function did not affect pros-
tate tumor cell metastasis. These results support the 
notion that overexpressed SRC-1 may be still a dan-
gerous factor in hormonally promoted cancers such 
as breast and prostate cancers.   
Further aiming to determine why our in vivo 
data in TRAMP mice did not correspond with cell 
line findings, we measured SRC-3 protein levels in 
advanced prostate tumors in SRC-1-/-/TRAMP mice. 
Interestingly, SRC-3 levels were significantly elevated 
in both SRC-1-/-/TRAMP and WT/TRAMP mice. In 
contrast, SRC-1 was expressed at relatively constant 
level in tumor cells throughout progression. These 
results suggest either a compensatory role for SRC-3 
in SRC-1 mediated functions or a primacy of SRC-3 in 
mediating prostate tumorigenesis in the TRAMP 
model. The notion of partial redundancy between 
SRC-1 and SRC-3 in prostate carcinogenesis is con-
sistent with multiple lines of evidence demonstrated 
in previous studies. First, both SRC-1 and SRC-3 in-
teracted with multiple nuclear receptors and expres-
sion of either SRC-1 or SRC-3 could promote the re-
ceptor-mediated gene transcription. Second, although 
SRC-1 null mice had nearly normal development and 
growth and most SRC-3 null mice were viable and 
had normal life span, most of SRC-1 and SRC-3 dou-
ble knockout mice were lethal before birth (reviewed 
in ref. 23). 
SRC-3 may act as a prostate cancer oncogene via 
several mechanisms. In the simplest case, it may di-
rectly coactivate AR-responsive transcriptional pro-
files in luminal epithelial cells. Alternatively, it may 
act outside of the luminal epithelial cell to stimulate 
the secretion of a diffusible growth factor. Such a me-
diator may be either a paracrine signal or an endo-Int. J. Biol. Sci. 2009, 5 
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crine hormone, such as IGF-1, a molecule associated 
with prostate cancer progression. SRC-3 has been 
shown to maintain IGF-1 in circulation by regulating 
IGFBP-3 mRNA levels in multiple tissues. Global 
SRC-3 deletion decreases systemic IGF-1 levels and 
retards somatic growth (22). SRC-3-deficient mam-
mary tumors also expressed lower IGF-1 mRNA (12). 
Finally, SRC-3 may be relevant in tumor cells not de-
rived form the luminal epithelium. Precursor cell 
populations, capable of differentiation to multiple 
lineages within a given tumor have been identified in 
multiple cancers. SRC-3 may be relevant for the ex-
pansion or progression of a precursor population in 
the prostate that gives rise to tumor cells histologi-
cally resembling luminal epithelial cells. Identifying 
the role of SRC-3 in prostate cancer will require gene 
deletion targeted to luminal epithelial cells as well as 
other prostatic cell types.   
In conclusion, we demonstrate here that SRC-1 
expression during mouse prostate carcinogenesis is 
relatively consistent and that SRC-1 deletion does not 
alter prostate tumor initiation, growth or progression 
in TRAMP mice. In contrast, SRC-3 is overexpressed 
during prostate carcinogenesis, indicating differential 
regulatory mechanisms for SRC-1 and SRC-3 pro-
moters in the prostate tumor cells. The SRC-3 may 
p l a y  a  d o m i n a n t  r o l e  v e r s u s  S R C - 1  i n  p r o m o t i n g  
prostate cancer progression in TRAMP mice. How-
ever, questions as to a role for increased SRC-1 in ag-
gressive patient tumors indicate this coactivator war-
rant future assessment. 
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